KAM
MDGL icon

Kazazian Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Kazazian Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,300
Closed -$1.33M – 76
2024
Q4 		$1.33M Buy
+4,300
New +$1.21M 1.01% 22

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kazazian Asset Management's MDGL Position: Q2 2025 in Review

Kazazian Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 955 shares — an estimated $316K sold.

Kazazian Asset Management first reported a position in MDGL in Q3 2018 and held it in 3 quarters. The position peaked at $316K in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Kazazian Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 955 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $316K.
  • Kazazian Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Kazazian Asset Management's Madrigal Pharmaceuticals position peaked at $316K in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Kazazian Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.